<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Isis Pharmaceuticals Inc. | Company News & Executive Profiles - ISIS | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Isis Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="31" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Genzyme's Renagel / Renvela Franchise: Investors Would Be Wise to Reevaluate]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175269-genzyme-s-renagel-renvela-franchise-investors-would-be-wise-to-reevaluate%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[This is a follow up to my previous post regarding the news that development of Genzyme&#8217;s GENZ follow-on product to its Renagel/Renvela franchise is being discontinued. The product, named GENZ-644470, is an advanced phosphate binder APB that was hoped to have demonstrated a superior clinical profile compared to predecessor Renvela....]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 04:31:44 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mark+mitchell.html"><![CDATA[Mark Mitchell]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">GENZ,ISIS</category>
	</item>
	<item>
		<title><![CDATA[Genzyme's Very Bad Year]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174932-genzyme-s-very-bad-year%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Even before the FDA&#8217;s ominous announcement last week that it had found things that really should not be there in vials of Genzyme&#8217;s GENZ enzyme replacement products, the US biotech was certainly having a personal annus horribilis.          ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 23 Nov 2009 01:32:12 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">GENZ,ISIS</category>
	</item>
	<item>
		<title><![CDATA[ISIS' Short-Term Trends Demonstrate When Technical Analysis Is Important]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173457-isis-short-term-trends-demonstrate-when-technical-analysis-is-important%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Curious Investor submits:  This is a follow up to my post, &#8220;ISIS Pharmaceuticals breaches long term support.&#8221; As many of you may know, posts from this blog are often though not always syndicated on SeekingAlpha.com. In the case of my previous post on ISIS, I caught significant flack...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 16 Nov 2009 01:29:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/the+curious+investor.html"><![CDATA[The Curious Investor]]></category>
		<category domain="http://resources.bnet.com/topic/blackstone+group+lp.html"><![CDATA[Blackstone Group LP]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">BX,ISIS</category>
	</item>
	<item>
		<title><![CDATA[Isis Pharma No Longer Paints a Profoundly Bullish Picture]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F164877-isis-pharma-no-longer-paints-a-profoundly-bullish-picture%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Curious Investor submits:  I highlighted Isis Pharmaceuticals ISIS a few weeks ago believing that a sell-off causing a price decline from $19 to $16/share was a prime opportunity to buy a potential high-growth business. It seems, however, that my proclamation may not have been entirely correct. And, post...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 05 Oct 2009 11:18:28 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/the+curious+investor.html"><![CDATA[The Curious Investor]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ISIS</category>
	</item>
	<item>
		<title><![CDATA[ISIS Makes (Anti) Sense (and Value)]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F155356-isis-makes-anti-sense-and-value%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Curious Investor submits:  Since bottoming near the end of 2008, ISIS Pharmaceuticals ISIS has been one of the hottest stocks in the first half of 2009. by The Curious Investor]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 11 Aug 2009 04:35:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+curious+investor.html"><![CDATA[The Curious Investor]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ISIS</category>
	</item>
	<item>
		<title><![CDATA[Isis Pharmaceuticals Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154344-isis-pharmaceuticals-inc-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Isis Pharmaceuticals Inc. ISIS   Q2 2009 Earnings Call   August 06, 2009; 8:30 am ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 06 Aug 2009 09:45:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ISIS</category>
	</item>
	<item>
		<title><![CDATA[Isis Pharmaceuticals Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-329161.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from Mark Monane with Needham; please proceed. Mark Monane - Needham Good morning everybody and thanks for reviewing your progress with us. A couple of questions here; you presented some nice data on the efficacy of mipomersen, can you please update...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 06 Aug 2009 08:45:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ISIS</category>
	</item>
	<item>
		<title><![CDATA[Isis Generating Impressive Oncology, Diabetes Data]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F145019-isis-generating-impressive-oncology-diabetes-data%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   By Jason Napodano, CFA At perhaps the two biggest industry trade conferences of the year, the American Society of Clinical Oncology (ASCO) and the American Diabetes Association (ADA), Isis Pharmaceuticals ISIS and/or its partners presented encouraging pre-clinical and early-stage clinical data showing the potential power of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 24 Jun 2009 12:59:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ISIS</category>
	</item>
	<item>
		<title><![CDATA[Isis, Genzyme May Have a Winning Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F138866-isis-genzyme-may-have-a-winning-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  Isis Pharmaceuticals ISIS has had a long, tough history developing antisense-based therapeutics. I've lost count of the number of promising candidates they've had (and promising deals they've signed). But the latest one seems to be progressing: mipomersen, designed to block production of the ApoB lipoprotein. ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 21 May 2009 01:19:02 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">GENZ,ISIS</category>
	</item>
	<item>
		<title><![CDATA[Isis Pharmaceuticals, Inc., Q1 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-299979.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions.  Our first question we go to Salveen Kochnover - Collins Stewart. Salveen Kochnover - Collins Stewart Stan, are there any plans to conduct MRI studies for mipomersen in patients with high baseline steatosis levels. Dr. Stanley Crooke Yes, Salveen, there are plans to do...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 07 May 2009 12:14:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/isis+pharmaceuticals+inc..html"><![CDATA[Isis Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ISIS</category>
		<category domain="tickers">ISIS</category>
	</item>
</channel>
</rss>
